Background: Type 3 neuroendocrine tumors of the stomach (type 3 NETV) are very rare subtypes of NETV with poor prognosis, not fully understood biology and not well investigated diagnostic and therapeutic procedures. The aim of the study was to analyze tumor biology and the outcome of differentiated treatment in patients with type 3 neuroendocrine tumors of the stomach.
Methods: A prospective 10 years follow up of five patients with type 3 NETV treated in our institution was undertaken.
Results: We investigated and followed up for 11 years five patients with histopathologically confirmed type 3 NETV. The diagnosis and gastric resection (total 3/5, partial 2/5, palliative 1/5) was performed 312 months after first tumor related symptoms presentation 5/5. The solitary tumors 5/5, were from 20 to 90 mm in diameter, located in fundus 4/5 and in cardia 1/5, infiltration beyond submucosa occurred in all cases. Metastases to regional lymph nodes were present in 5/5 cases during surgery, liver and distant (peritoneum, retroperitoneal space) metastases occurred in 4/5 in 011 months from diagnosis/gastrectomy. Chemotherapy was given in 3/5 in 26 months from diagnosis/gastrectomy. One patient was treated with 90Y in 6 months after diagnosis. 3/5 patients died in 818 months from diagnosis/gastrectomy. 2/5 patients are alive in 2038 months from diagnosis/gastrectomy, 1/5 patient is free of disease in 38 months from diagnosis/gastrectomy.
Conclusions: The increasing number of type 3 NETV related probably to improved diagnostic methods and their poor prognosis require more profound investigation of the tumor biology and improvement of the treatment procedures.
30 Apr - 04 May 2011
European Society of Endocrinology